Two Sigma Securities’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Two Sigma Securities’s Portfolio ATXI Stock Details ATXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,374	Closed	-$26.3K	–	3820
2024 Q1	$26.3K	Buy	2,374 +2,007	+547%	+$23.8K	﹤0.01%	2646
2023 Q4	$4.43K	Buy	367 +174	+90%	+$4.07K	﹤0.01%	2889
2023 Q3	$10.2K	Buy	+193	New	+$13.6K	﹤0.01%	2692
2022 Q4	–	Sell	-189	Closed	-$143K	–	3382
2022 Q3	$143K	Buy	189 +166	+722%	+$53.2K	﹤0.01%	2040
2022 Q2	$7K	Sell	23 -24	-51%	-$9.24K	﹤0.01%	2094
2022 Q1	$25K	Buy	47 +29	+161%	+$21.7K	﹤0.01%	1950
2021 Q4	$18K	Buy	+18	New	+$26K	﹤0.01%	1426

Other funds holding ATXI

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Securities's ATXI Position: Q2 2024 in Review

Two Sigma Securities sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q2 2024, closing a stake of 2,374 shares — an estimated $26.3K sold.

Two Sigma Securities first reported a position in ATXI in Q4 2021 and held it in 7 quarters. The position peaked at $143K in Q3 2022. 9 funds tracked by Wall St. Rank hold ATXI as of Q2 2024.

Two Sigma Securities reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Two Sigma Securities sold 2,374 Avenue Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $26.3K.
Two Sigma Securities first reported a position in Avenue Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Two Sigma Securities's Avenue Therapeutics, Inc. Common Stock position peaked at $143K in Q3 2022.
9 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Two Sigma Securities's 13F filing for Q2 2024, filed 14 Aug 2024.